0001700449-17-000002.txt : 20170309
0001700449-17-000002.hdr.sgml : 20170309
20170309130828
ACCESSION NUMBER: 0001700449-17-000002
CONFORMED SUBMISSION TYPE: D
PUBLIC DOCUMENT COUNT: 1
ITEM INFORMATION: 06b
FILED AS OF DATE: 20170309
DATE AS OF CHANGE: 20170309
EFFECTIVENESS DATE: 20170309
FILER:
COMPANY DATA:
COMPANY CONFORMED NAME: Arix Bioscience plc
CENTRAL INDEX KEY: 0001700449
IRS NUMBER: 000000000
STATE OF INCORPORATION: X0
FILING VALUES:
FORM TYPE: D
SEC ACT: 1933 Act
SEC FILE NUMBER: 021-282151
FILM NUMBER: 17677675
BUSINESS ADDRESS:
STREET 1: 20 BERKELEY SQUARE
CITY: LONDON
STATE: X0
ZIP: W1J 6EQ
BUSINESS PHONE: 44(0)20 7290 1050
MAIL ADDRESS:
STREET 1: 20 BERKELEY SQUARE
CITY: LONDON
STATE: X0
ZIP: W1J 6EQ
D
1
primary_doc.xml
X0707
D
LIVE
0001700449
Arix Bioscience plc
20 BERKELEY SQUARE
LONDON
X0
UNITED KINGDOM
W1J 6EQ
44(0)20 7290 1050
UNITED KINGDOM
Arix Bioscience Limited
Perceptive Bioscience Investments Limited
None
Other
Public Company in the United Kingdom
true
2015
Joseph
Anderson
20 BERKELEY SQUARE
LONDON
X0
UNITED KINGDOM
W1J 6EQ
Executive Officer
Director
Christopher
Evans
20 BERKELEY SQUARE
LONDON
X0
UNITED KINGDOM
W1J 6EQ
Executive Officer
Director
Jonathan
Peacock
20 BERKELEY SQUARE
LONDON
X0
UNITED KINGDOM
W1J 6EQ
Executive Officer
Director
John
Mutton of Furness
20 BERKELEY SQUARE
LONDON
X0
UNITED KINGDOM
W1J 6EQ
Director
James
Rawlingson
20 BERKELEY SQUARE
LONDON
X0
UNITED KINGDOM
W1J 6EQ
Executive Officer
Director
John
Banham
20 BERKELEY SQUARE
LONDON
X0
UNITED KINGDOM
W1J 6EQ
Director
David
U'Prichard
20 BERKELEY SQUARE
LONDON
X0
UNITED KINGDOM
W1J 6EQ
Director
Franz
Humer
20 BERKELEY SQUARE
LONDON
X0
UNITED KINGDOM
W1J 6EQ
Director
Trevor
Jones
20 BERKELEY SQUARE
LONDON
X0
UNITED KINGDOM
W1J 6EQ
Director
Other Health Care
Decline to Disclose
- 06b
false
2017-02-22
false
true
false
0
Jefferies International Limited
None
None
None
68 Upper Thames Street
London
X0
UNITED KINGDOM
EC4V 2AF
CA
CALIFORNIA
IL
ILLINOIS
false
121000000
17506964
103493036
Offering was launched as public offering in the United Kingdom and available to U.S. investors by private placement. Offering raised approx. $121,000,000 total with approx. $17,506,964 raised in the U.S. and approx. $103,693,036 in the U.K.
false
4
536417
0
550000
true
false
Arix Bioscience plc
James Rawlingson
James Rawlingson
Director
2017-03-09